

**Table I.** Demographic profile, details of mobilisation regimen, CD34 count and HSC harvest, details of engraftment of patients.

| S. No | Age (Yr.) | Gender (M/F) | Weight (kg) | Diagnosis                        | Mobilization Chemotherapy                            | Prior receipt of Platinum group of drugs (Y/N) | Prior receipt of Radiotherapy (Y/N) | Peg-GCSF dose (mg) | GCSF before harvest (10mcg/kg) | Day of harvest from Peg-GCSF | Day of harvest from start of chemo | CD34 count (/microliter) on the day before collection | CD34 count (/microliter) at the start of collection | CD34 count (/microliter) of collected product | Product volume (ml) | Stem cell dose (million/kg) collected | Day of Neutrophil engraftment post autologous HSCT | Day of Platelet engraftment post autologous HSCT | Duration of follow-up post HSC harvest (months) |
|-------|-----------|--------------|-------------|----------------------------------|--|--|-------------------------------------|--------------------|--------------------------------|------------------------------|------------------------------------|---|---|---|---------------------|---------------------------------------|--|--|---|
| 1     | 2         | M            | 9.6         | Stage 4 NB                       | Cyclo 2g/m <sup>2</sup>                              | Y  | N                                   | 2                  | -                              | 11                           | 12                                 | NA  | 206   | 1756  | 180                 | 32.9                                  | 9  | 15   | 16  |
| 2     | 3         | M            | 12.8        | Stage 4 NB                       | Vinc 1.5mg/m <sup>2</sup><br>Cyclo 2g/m <sup>2</sup> | Y  | N                                   | 2                  | -                              | 10                           | 11                                 | 490   | NA  | 4002  | 70                  | 28.4                                  | 8  | 10   | 6   |
| 3     | 3         | M            | 11.1        | Stage 4 NB                       | Vinc1.5mg/m <sup>2</sup><br>Cyclo 2g/m <sup>2</sup>  | Y  | N                                   | 2                  | one dose                       | 10                           | 11                                 | 16  | 37  | 1164  | 100                 | 10.4                                  | 10   | 11   | 4   |
| 4     | 11        | M            | 35.5        | Metastatic EWS                   | VIDE   | N  | N                                   | 4                  | one dose                       | 9                            | 12                                 | 44  | 102   | 4023  | 120                 | 13.5                                  | NA   | NA   | 4   |
| 5     | 10        | F            | 24.5        | Metastatic malignant GCT (ovary) | TIP  | Y  | N                                   | 3                  | -                              | 8                            | 14                                 | 9   | NA  | 412   | 245                 | 4.1                                   | 11   | 18   | 38  |
| 6     | 7         | M            | 25.4        | Recurrent Anaplastic             | HEADST ART-2A  | N  | Y                                   | 3                  | -                              | 10                           | 14                                 | NA  | 200   | 6223  | 110                 | 26.9                                  | 9  | 13   | 20  |

|   |    |   |      |                |                                     |   |   |   |   |    |    |     |     |       |     |      |    |    |   |
|---|----|---|------|----------------|-------------------------------------|---|---|---|---|----|----|-----|-----|-------|-----|------|----|----|---|
|   |    |   |      | Epend<br>ymoma |                                     |   |   |   |   |    |    |     |     |       |     |      |    |    |   |
| 7 | 15 | M | 32   | Relapsed<br>MB | HEADST<br>ART-2A                    | N | Y | 4 | - | 12 | 15 | 121 | 260 | 9236  | 210 | 60   | 10 | 12 | 6 |
| 8 | 13 | F | 28.5 | Relapsed<br>OS | Cyclo 2g/<br>m2                     | Y | N | 3 | - | 10 | 11 | 10  | 30  | 703   | 250 | 6.3  | 12 | 11 | 5 |
| 9 | 5  | M | 17.7 | Relapsed<br>WT | Vinc<br>1.5mg/m2<br>Cyclo 2g/<br>m2 | Y | N | 2 | - | 8  | 10 | NA  | 330 | 11090 | 85  | 53.2 | 8  | 23 | 8 |

Yr.- Year, M-Male, F-Female, NB-Neuroblastoma, EWS-Ewings sarcoma, GCT-Germ cell tumor, MB- Medulloblastoma, OS- osteosarcoma, WT- Wilms tumor, Cyclo- Cyclophosphamide, Vinc- Vincristine, Y- yes, N- no, chemo-chemotherapy, NA- not available